35-usc-103

10 cases — ← All topics

Case Title Lower Court Docketed Status Flags Tags Question Presented
23-739 Jodi A. Schwendimann, fka Jodi A. Dalvey v. Neenah, Inc., et al. Federal Circuit 2024-01-09 Denied 35-usc-103 federal-circuit-review ksr-standard ksr-v-teleflex obviousness patent-law primary-reference prior-art wbip-v-kohler yeda-v-mylan In conducting an obviousness analysis under 35 U.S.C. § 103, did the Federal Circuit err in holding that there "is no basis in our case law" for requi…
23-575 Fleur Tehrani v. Hamilton Technologies LLC Federal Circuit 2023-11-28 Denied 35-usc-103 federal-circuit obviousness patent patent-invalidation patent-law posita prior-art 1. Whether the Court of Appeals for the Federal Circuit erred by declaring a non-expert as a POSITA despite all the evidence presented to the contrary…
22-11 SawStop Holding LLC v. United States Patent and Trademark Office, et al. Federal Circuit 2022-07-05 Denied Response Waived 35-usc-101 35-usc-102 35-usc-103 judicial-authority non-statutory-double-patenting patent patent-eligibility patent-law statutory-interpretation ultra-vires The Patent Act adopted by Congress provides that a person shall be entitled to a patent if an invention meets three conditions: the eligibility condit…
21-893 Apotex Inc., et al. v. Cephalon, Inc., et al. Federal Circuit 2021-12-16 Denied 35-usc-103 drug-reformulation inventive-process ksr-v-teleflex motivation motivation-to-combine obviousness obviousness-standard patent patent-law person-of-ordinary-skill prior-art Whether claimed inventions involving reformulating and administering an old drug in ways that are no better than prior techniques, and which had been …
20-1119 Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al. Federal Circuit 2021-02-16 Denied Amici (3)Response RequestedResponse WaivedRelisted (2) 35-usc-103 graham-factors graham-v-john-deere hindsight-bias innovation innovation-protection nonobviousness-indicia objective-indicia obviousness-standard patent patent-law Whether a court must consider objective indicia of nonobviousness together with the other factors bearing on an obviousness challenge before making an…
20-158 SRAM, LLC v. FOX Factory, Inc. Federal Circuit 2020-08-13 Denied Response Waived 35-usc-103 commercial-success federal-circuit graham-v-john-deere nonobviousness objective-indicia patent-act patent-claim patent-law person-of-ordinary-skill secondary-considerations statutory-interpretation In Graham v. John Deere Co. of Kansas City, 383 U.S. 1 (1966), this Court recognized the pivotal importance of "objective indicia" of nonobviousness (…
19-966 Emerson Electric Co. v. SIPCO, LLC Federal Circuit 2020-02-03 GVR Response RequestedResponse WaivedRelisted (2) 35-usc-101 35-usc-103 35-usc-324 administrative-law america-invents-act cbm-patent covered-business-method judicial-review patent patent-review patent-trial-and-appeal-board statutory-interpretation In the America Invents Act, Congress authorized the Patent Trial and Appeal Board to review whether certain patents, called Covered Business Method (C…
18-1072 James J. Macor v. United States Patent and Trademark Office Federal Circuit 2019-02-15 Denied Response Waived 35-usc-102 35-usc-103 administrative-law analogous-art obviousness obviousness-standard patent patent-examination patent-law prior-art statutory-interpretation In making rejections under 35 U.S.C. § 103(a) as obvious, what standard should be applied in determining whether prior art is "analogous," and, if the…
18-692 Mylan Pharmaceuticals Inc., et al. v. UCB, Inc., et al. Federal Circuit 2018-11-27 Denied Amici (3)Response Waived 35-usc-103 double-patenting federal-circuit graham-factors graham-v-john-deere invention-disclosure lead-compound-test obviousness patent-eligibility patent-law patent-law-doctrine-of-double-patenting patent-validity prior-art 1. This Court has long held that "no patent can issue for an invention actually covered by a former patent, especially to the same patentee." Miller v…
18-441 Accord Healthcare, Inc., et al. v. UCB, Inc., et al. Federal Circuit 2018-10-09 Denied Amici (1)Response Waived 35-usc-103 lead-compound obviousness patent patent-invalidation patent-law pharmaceutical pharmaceutical-compound prior-art Did the Federal Circuit commit error in holding that a patent claim to an obvious modification of a prior art compound was not invalid as obvious unde…